Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could chatting with AI keep aging brains sharp?

NCT ID NCT07751510

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether a daily conversation platform powered by artificial intelligence can support cognitive health in older adults at high risk of dementia. Participants engage in voice-based conversations tailored to their interests, designed to exercise memory, attention, language, and problem-solving skills. The study first checks the platform's ease of use in a small group, then randomly assigns 60 older adults to either the AI conversations, interest-based news reading, or health education for 12 weeks. Researchers will compare changes in cognitive function, emotional well-being, and social connection to see if the platform is practical and potentially beneficial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A voice-based cognitive stimulation program delivered through a large language model-driven conversational platform
What this could lead to
If effective, this AI conversation platform could offer a home-based, engaging way to support memory, attention, and social connection in older adults at risk of dementia.
What could go wrong
This is an early feasibility study with a small number of participants, so results may not be conclusive. The platform's benefits are uncertain, and it is not a proven treatment for preventing dementia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Stage 1: Feasibility Study Participants must belong to one of the following groups: Healthy younger adults aged 18 to 40 years. Older adults with normal cognitive function aged 65 years or older and a Montreal Cognitive Assessment score of 24 or higher. Older adults with cognitive impairment aged 65 years or older and a Montreal Cognitive Assessment score of 18 to 23. Participants must have completed at least elementary school, corresponding to 6 or more years of education. Participants must be able to read and write Chinese, communicate in Chinese, and understand the study content. Participants must be able to use a tablet or smartphone independently or with assistance from a family member. Participants must have sufficient hearing and vision, with usual corrective devices if needed, to complete the study tasks. Stage 2: Preliminary Efficacy Study Participants must be aged 65 years or older. Participants must be considered at high risk of dementia by meeting at least one of the following conditions: 1. Subjective cognitive decline: A Subjective Cognitive Decline Questionnaire score greater than 7 out of 24. A response of yes to both of the following questions: Compared with your previous usual condition, do you have memory problems? Have your family members or close contacts noticed memory problems compared with your previous condition? Performance within the normal range on standardized cognitive tests, defined as scores no more than 1.5 standard deviations below age- and education-adjusted norms on the Color Trails Test and memory-related assessments. 2. Mild cognitive impairment: A diagnosis of mild cognitive impairment made by a neurologist or psychiatrist according to accepted diagnostic criteria. Evidence of memory performance at least 1.5 standard deviations below age- and education-adjusted normative values on at least one subtest of the Wechsler Memory Scale, Third Edition. 3. Limited social interaction: Living alone, living with a person who cannot provide care, or living with a person who is absent for at least 3 days per week; or A score below 12 on the 6-item Lubben Social Network Scale. 4. Chronic disease: A physician diagnosis of hypertension or diabetes for at least 1 year; and A need for ongoing medication or lifestyle management. Participants must have completed at least elementary school, corresponding to 6 or more years of education. Participants must be able to read and write Chinese, communicate in Chinese, and understand news and study-related content. Participants must be able to use a tablet or smartphone independently or with assistance from a family member. Participants must have sufficient hearing and vision, with usual corrective devices if needed, to complete the conversation and reading tasks. Exclusion Criteria A diagnosis of dementia or a severe neurodegenerative disorder, such as moderate-to-advanced Parkinson disease or Huntington disease. A history of a severe psychiatric disorder, such as schizophrenia or severe bipolar disorder, or current acute psychiatric symptoms that may interfere with understanding or responding during conversations. A major neurological event within the previous 6 months, such as stroke or severe traumatic brain injury, that may substantially affect cognitive or language function. Severe hearing, speech, or language impairment that prevents basic verbal communication, even when assistive devices are used. An acute medical illness, active infection, or any condition considered by a physician to make study participation inappropriate. Inability to complete a 20-minute conversation task or unwillingness to allow collection of interaction data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Subjective cognitive decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.